Effects of t-type calcium channel blockers on renal function and aldosterone in patients with hypertension: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Li, Xue ^a   Sheng Yang, Mao ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; AZELNIDIPINE; BENAZEPRIL; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFONIDIPINE; ENALAPRIL; MANIDIPINE; NIFEDIPINE; PERINDOPRIL; RENIN INHIBITOR; VALSARTAN;

ALBUMIN URINE LEVEL; COMPARATIVE STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; META ANALYSIS; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; ADULT; AGED; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; COMPLICATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALDOSTERONE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CASE-CONTROL STUDIES; HUMANS; HYPERTENSION; MIDDLE AGED; PROTEINURIA;

EID: 84908148204     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109834     Document Type: Review

References (48)

1. Griffin KA, Picken MM, Bakris GL, Bidani AK (1999) Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 55: 1849-1860.
2. Tomino Y, Shimizu Y, Hamada C, Kurusu A, Ohsawa I, et al. (2011) One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease. J Nephrol 24: 756-763.
3. 2+ channels and drug development. Pharmacol Sci 99: 214-220.
4. Marin R, Gorostidi M, Fernandez-Vega F, Alvarez-Navascues R (2005) Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Kidney Int Suppl 99: 52-56.
5. Wang T, Takabatake T (2005) Effects of vasopeptidase inhibition on renal function and tubuloglomerular feedback in spontaneously hypertensive rats. Hypertens Res 28: 611-618.
6. 2+ channels in renal microcirculation. J Pharmacol Sci 99: 221-227.
7. Caldicott WJ, Taub KJ, Margulies SS, Hollenberg NK (1981) Angiotensin receptors in glomeruli differ from those in renal arterioles. Kidney Int 19: 687-693.
8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869.
9. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, et al. (2005) Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365: 939-946.
10. Sato A, Hayashi K, Saruta T (2005) Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18: 44-49.
11. Chen GJ, Yang MS (2013) The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials. PLoS ONE 8: e57854.
12. Konoshita T, Makino Y, Kimura T, Fujii M, Morikawa N, et al. (2013) A Crossover Comparison of Urinary Albumin Excretion as a New Surrogate Marker for Cardiovascular Disease among 4 Types of Calcium Channel Blockers. Int J Cardiol 166: 448-452.
13. Takenaka T, Seto T, Okayama M, Kojima E, Nodaira Y, et al. (2012) Long-Term Effects of Calcium Antagonists on Augmentation Index in Hypertensive Patients with Chronic Kidney Disease: A Randomized Controlled Study. Am J Nephrol 35: 416-423.
14. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Koide H, et al. (2011) Calcium Channel Blocker Inhibition of Age and Rage Axis Limits Renal Injury in Nondiabetic Patients with Stage I or Ii Chronic Kidney Disease. Clin Cardiol 34: 372-377.
15. Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, et al. (2011) Benidipine Reduces Albuminuria and Plasma Aldosterone in Mild-to-Moderate Stage Chronic Kidney Disease with Albuminuria. Hypertens Res 34: 268-273.
16. Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, et al. (2011) Additive Antioxidative Effects of Azelnidipine on Angiotensin Receptor Blocker Olmesartan Treatment for Type 2 Diabetic Patients with Albuminuria. Hypertens Res 34: 935-941.
17. Nakano N, Ishimitsu T, Takahashi T, Inada H, Okamura A, et al. (2010) Effects of Efonidipine, an L- and T-Type Calcium Channel Blocker, on the Renin-Angiotensin-Aldosterone System in Chronic Hemodialysis Patients. Int Heart J 51: 188-192.
18. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, et al. (2010) Comparative Effects of Benidipine and Amlodipine on Proteinuria, Urinary 8-Ohdg, Urinary L-Fabp, and Inflammatory and Atherosclerosis Markers in Early-Stage Chronic Kidney Disease. Am J Med Sci 339: 157-163.
19. Tsutamoto T, Tanaka T, Nishiyama K, Yamaji M, Kawahara C, et al. (2009) Long-Term Effect of Efonidipine Therapy on Plasma Aldosterone and Left Ventricular Mass Index in Patients with Essential Hypertension. Hypertens Res 32: 670-674.
20. Sasaki H, Saiki A, Endo K, Ban N, Yamaguchi T, et al. (2009) Protective Effects of Efonidipine, a T- and L-Type Calcium Channel Blocker, on Renal Function and Arterial Stiffness in Type 2 Diabetic Patients with Hypertension and Nephropathy. J Atheroscler Thromb 16: 568-575.
21. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K (2009) Comparison of the Antiproteinuric Effects of the Calcium Channel Blockers Benidipine and Amlodipine Administered in Combination with Angiotensin Receptor Blockers to Hypertensive Patients with Stage 3-5 Chronic Kidney Disease. Hypertens Res 32: 270-275.
22. Martinez-Martin FJ, Saiz-Satjes M (2008) Add-on Manidipine Versus Amlodipine in Diabetic Patients with Hypertension and Microalbuminuria: The Amandha Study. Expert Rev Cardiovasc Ther 6: 1347-1355.
23. Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T, et al. (2007) Comparison of the Effects of Efonidipine and Amlodipine on Aldosterone in Patients with Hypertension. Hypertens Res 30: 691-697.
24. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, et al. (2007) Azelnidipine Reduces Urinary Protein Excretion and Urinary Liver-Type Fatty Acid Binding Protein in Patients with Hypertensive Chronic Kidney Disease. Am J Med Sci 333: 321-326.
25. Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, et al. (2007) Efonidipine Reduces Proteinuria and Plasma Aldosterone in Patients with Chronic Glomerulonephritis. Hypertens Res 30: 621-626.
26. Oshima T, Ozono R, Yano Y, Higashi Y, Teragawa H, et al. (2005) Beneficial Effect of T-Type Calcium Channel Blockers on Endothelial Function in Patients with Essential Hypertension. Hypertens Res 28: 889-894.
27. Ueshiba H, Miyachi Y (2004) Effects of the Long-Acting Calcium Channel Blockers, Amlodipine, Manidipine and Cilnidipine on Steroid Hormones and Insulin Resistance in Hypertensive Obese Patients. Intern Med 43: 561-565.
28. Bellinghieri G, Mazzaglia G, Savica V, Santoro D (2003) Effects of Manidipine and Nifedipine on Blood Pressure and Renal Function in Patients with Chronic Renal Failure: A Multicenter Randomized Controlled Trial. Ren Fail 25: 681-689.
29. Han RQ, Luo CL, Jiang M, Li HY, Shan FJ (2013) Observed the efficacy of benidipine combined with benazepril treatment of hypertension nephropathy. Clinical drug of the world 7: 401-404. (in Chinese).
30. Gong ML, Gao YX, Zhang J (2012) Benidipine combined with valsartan on renal function in patients with essential hypertension. Chinese Medicine 14: 95-96+99. (in Chinese).
31. Gan JS, Gan L (2012) Effect of valsartan and benidipine on renal function in patients with essential hypertension with proteinuria. China Pharmaceutical Guide 27: 201-202. (in Chinese).
32. Dong B, Xiao Qu B (2011) Benidipine and perindopril in elderly hypertensive patients with proteinuria affect renal function. Journal of China Modern Medicine 11: 54-56. (in Chinese).
33. Peng T, Hu Z, Xia Q, Bei Jiang, Xianhua Li, et al. (2009) A Comparative Study of the Renoprotective Effects of Benidipine and Valsartan in Primary Hypertensive Patients with Proteinuria. Arzneimittelforschung 59: 647-650.
34. Del Vecchio L, Pozzi M, Salvetti A, Maschio G, Fusaroli M, et al. (2004) Efficacy and Tolerability of Manidipine in the Treatment of Hypertension in Patients with Non-Diabetic Chronic Kidney Disease without Glomerular Disease. Prospective, Randomized, Double-Blind Study of Parallel Groups in Comparison with Enalapril. J Nephrol 17: 261-269.
35. Hayashi K, Kumagai H, Saruta T (2003) Effect of Efonidipine and Ace Inhibitors on Proteinuria in Human Hypertension with Renal Impairment. Am J Hypertens 16: 116-122.
36. Fan ZG, Liu ZA (2010) Advances in anti-hypertensive drugs and clinical evaluation. Chinese pharmacy 42: 4011-4013. (in Chinese).
37. Heller J, Horacek V (1990) The effect of two different calcium antagonists on the glomerular haemodynamics in dogs. Eur J Physiol 415: 751-755.
38. Dietz JR, Davis JO, Freeman RH, Villarreal D, Echtenkamp SF (1983) Effects of intrarenal infusion of calcium entry blockers in anesthetized dogs. Hypertension 5: 482-488.
39. Abe Y, Komori T, Miura K, Takada T, Imanishi M, et al. (1983) Effects of the calcium antagonist nicardipine on renal function and renin release in dogs. J Cardiovasc Pharmacol 5: 254-259.
40. Roy M, Guthrie GP, Holladay FP, Kotchen TA (1983) Effects of verapamil on renin and aldosterone in the dog and rat. Am J Physiol 245: E410-E416.
41. 2+ Channel Subtypes and Pharmacology in the Kidney. Circ Res 100: 342-353.
42. Perez-Reyes E (2003) Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 83: 117-161.
43. 2+ currents by efonidipine: possible mechanism for chronotropic effect. Eur J Pharmacol 349: 351-357.
44. 2+ channels in rat hippocampal CA1 pyramidal neurons. Brain Res 813: 121-127.
45. 2+ channels by Ro 40-5967. Circ Res 75: 144-148.
46. 2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol 48: 54-549.
47. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T (1996) Disparate effects renal of calcium antagonists microcirculation. Hypertens Res 19: 31-36.
48. Imagawa K, Okayama S, Takaoka M, Kawata H, Naya N, et al. (2006) Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 47: 133-138.